Sangamo Therapeutics/$SGMO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sangamo Therapeutics
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Ticker
$SGMO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
183
ISIN
US8006771062
Website
SGMO Metrics
BasicAdvanced
$122M
-
-$0.38
1.46
-
Price and volume
Market cap
$122M
Beta
1.46
52-week high
$2.84
52-week low
$0.30
Average daily volume
5.5M
Financial strength
Current ratio
0.759
Quick ratio
0.601
Long term debt to equity
507.053
Total debt to equity
507.053
Interest coverage (TTM)
-24.91%
Profitability
EBITDA (TTM)
-76.077
Gross margin (TTM)
-59.41%
Net profit margin (TTM)
-124.61%
Operating margin (TTM)
-126.73%
Effective tax rate (TTM)
0.18%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-46.95%
Return on equity (TTM)
-257.94%
Valuation
Price to revenue (TTM)
1.706
Price to book
23.6
Price to tangible book (TTM)
23.6
Price to free cash flow (TTM)
-2.423
Free cash flow yield (TTM)
-41.28%
Free cash flow per share (TTM)
-21.21%
Growth
Revenue change (TTM)
239.92%
Earnings per share change (TTM)
-79.70%
3-year revenue growth (CAGR)
-17.28%
10-year revenue growth (CAGR)
2.21%
3-year earnings per share growth (CAGR)
-32.37%
10-year earnings per share growth (CAGR)
0.63%
What the Analysts think about SGMO
Analyst ratings (Buy, Hold, Sell) for Sangamo Therapeutics stock.
SGMO Financial Performance
Revenues and expenses
SGMO Earnings Performance
Company profitability
SGMO News
AllArticlesVideos
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
Business Wire·1 day ago
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Business Wire·1 month ago
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sangamo Therapeutics stock?
Sangamo Therapeutics (SGMO) has a market cap of $122M as of June 25, 2025.
What is the P/E ratio for Sangamo Therapeutics stock?
The price to earnings (P/E) ratio for Sangamo Therapeutics (SGMO) stock is 0 as of June 25, 2025.
Does Sangamo Therapeutics stock pay dividends?
No, Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders as of June 25, 2025.
When is the next Sangamo Therapeutics dividend payment date?
Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders.
What is the beta indicator for Sangamo Therapeutics?
Sangamo Therapeutics (SGMO) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.